Previous 10 | Next 10 |
SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 42 ...
2023-12-20 13:34:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Although extremely risky, penny stocks can provide tactical value to a portfolio. The risk of losing it all is very real. Also, one should be willing to cut one’s losses if necessary...
First-in-class and best-in-class potential in NRAS-mutated melanoma and other RAS/MAPK pathway-altered solid tumors Naporafenib has been dosed in more than 500 patients to date, establishing its safety, tolerability, and preliminary proof-of-concept in multiple indications Pivotal...
2023-12-08 10:07:46 ET Penny stocks , defined as stocks trading under $5 per share, are known for their volatility. Even small pieces of news or unconfirmed rumors can send some penny stocks swinging wildly up or down in price. This extreme sensitivity makes them risky but also ...
2023-12-07 15:36:49 ET Penny stocks – the cheap stocks trading under $5 per share, offer investors massive upside potential alongside higher risk. Since even incremental price moves translate into huge percentage gains in the stock market, timing entries right can set you up for ...
2023-12-07 11:18:14 ET More on Erasca Seeking Alpha’s Quant Rating on Erasca Historical earnings data for Erasca Financial information for Erasca For further details see: Erasca CEO Lim buys stock worth $1.7M - filing
2023-12-07 10:22:26 ET More on Erasca Seeking Alpha’s Quant Rating on Erasca Historical earnings data for Erasca Financial information for Erasca For further details see: Erasca director Alexander Casdin discloses purchase of 30K shares
2023-12-07 08:27:08 ET MicroAlgo ( MLGO ) +74% plans to establish a practice base to train graduate students for the university. Altisource Asset Management ( AAMC ) +23% Asset case against six defendants in suit v. BlackRock, Pimco can proceed. ...
Gained alignment with global health authorities for pivotal Phase 3 SEACRAFT-2 trial design for naporafenib plus trametinib in NRAS mutant melanoma; initiation on track for H1 2024 Completed dose escalation and identified MTD for ERAS-801, supporting enrollment of expansion cohorts in r...
2023-11-17 17:01:57 ET Gainers: Cogent Biosciences ( COGT ) +3% . Erasca ( ERAS ) +3% . Vigil Neuroscience ( VIGL ) +3% . 2seventy ( TSVT ) +2% . Twist Biosciences ( TWST ) +2% . Losers: Nkarta ( NKTX ) -5% ...
News, Short Squeeze, Breakout and More Instantly...
Erasca Inc. Company Name:
ERAS Stock Symbol:
NASDAQ Market:
Oral presentation will feature updated HERKULES-3 results for ERK1/2 inhibitor ERAS-007 in combination with encorafenib and cetuximab in BRAFm col...
Oral presentation will feature updated HERKULES-3 results for ERK1/2 inhibitor ERAS-007 in combination with encorafenib and cetuximab in BRAFm colorectal cancer Poster presentations will feature SEACRAFT-1 Phase 1 trial design for naporafenib plus trametinib in RAS Q61X mutations, and p...
SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS) ("Erasca"), a clinical-stage precision oncology company singularly focu...